Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Gains from Sales and Divestitures: 2022-2025

Historic Gains from Sales and Divestitures for Organogenesis Holdings (ORGO) over the last 4 years, with Sep 2025 value amounting to $1.6 million.

  • Organogenesis Holdings' Gains from Sales and Divestitures rose 10.67% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 10.67%. This contributed to the annual value of $1.4 million for FY2024, which is 174.53% up from last year.
  • Organogenesis Holdings' Gains from Sales and Divestitures amounted to $1.6 million in Q3 2025, which was up 0.07% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, Organogenesis Holdings' Gains from Sales and Divestitures registered a high of $1.6 million during Q3 2025, and its lowest value of $239,245 during Q2 2022.
  • Moreover, its 3-year median value for Gains from Sales and Divestitures was $1.4 million (2024), whereas its average is $1.1 million.
  • Data for Organogenesis Holdings' Gains from Sales and Divestitures shows a peak YoY spiked of 230.35% (in 2024) over the last 5 years.
  • Quarterly analysis of 4 years shows Organogenesis Holdings' Gains from Sales and Divestitures stood at $249,106 in 2022, then surged by 109.81% to $522,651 in 2023, then soared by 174.53% to $1.4 million in 2024, then increased by 10.67% to $1.6 million in 2025.
  • Its Gains from Sales and Divestitures was $1.6 million in Q3 2025, compared to $1.6 million in Q2 2025 and $1.6 million in Q1 2025.